KALARIS THERAPEUTICS INC (KLRS)

NASDAQHealth CareBiotechnologySnapshot 2026-10-23

$1.87-6.03%

Close 2026-10-23 · 1-day change

Investment OutlookAs of Oct 24, 2026

What could strengthen or challenge KALARIS THERAPEUTICS INC’s outlook?

The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.

Higher potential upsideImproving expectations

Next-FY EPS estimate change · 30 days

Comparable estimates unavailable

+10% or more+5%0%−5%−10% or less

A matching fiscal period and sufficient coverage are required.

Higher risk of downsideWeakening expectations

One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.

How this is measured

The calculation requires same-period, same-provider snapshots, positive EPS, at least five analysts and a baseline within three days of the requested lookback.

Measure / period	Management expectations	Analyst expectations
Quarter ending 2026-12-30
Revenue	—	0
EPS	—	-0.543
Annual ending 2026-12-31
Revenue	—	0
EPS	—	-2.001
Annual ending 2027-12-31
Revenue	—	10M
EPS	—	-1.653

Management figures unavailable.

What the Thesis Depends On

Three published thesis conditions, with dated milestones shown separately.

Key Factor	Why It Matters	Current Status	Break Condition	Latest Evidence
Advance TH103 to Phase 3 clinical trials	Kalaris aims to start Phase 3 trials for TH103 soon.	Improving	TH103 does not start Phase 3 trials by end of 2026	Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Source date unavailableLast status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.
Maintain financial stability through private placements	A primary condition in KALARIS THERAPEUTICS INC's published investment case. The stated target is Raise at least $100 million by September 2027.	Intact	Cash raised falls below $100 million by September 2027	Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Source date unavailableLast status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.
Manage CFO transition to maintain financial leadership	A supporting condition in KALARIS THERAPEUTICS INC's published investment case. The stated target is Appoint a permanent CFO by end of 2026.	Intact	No permanent CFO appointed by end of 2026	Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Source date unavailableLast status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.

Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.

Incoming Evidence

Compare these dated observations with the operating requirements above

Expectations trend

Same fiscal period

FY2027 · fiscal year ending 2027-12-31 · fmp

FY2027 EPS$-1.65

$-1.63 → $-1.65 · observed estimates

FY2027 revenue$0.01B

$0.01B → $0.01B · observed estimates

Exact estimates & source dates

One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.

FY2027 estimate observations · fmp
Snapshot	EPS	Revenue	EPS / revenue analysts
2026-07-24	$-1.63	$10,000,000	6 / 5
2026-07-25	$-1.63	$10,000,000	6 / 5
2026-07-26	$-1.63	$10,000,000	6 / 5
2026-07-27	$-1.63	$10,000,000	6 / 5
2026-07-28	$-1.63	$10,000,000	6 / 5
2026-07-29	$-1.63	$11,428,570	8 / 7
2026-07-30	$-1.63	$11,428,570	8 / 7
2026-07-31	$-1.63	$11,428,570	8 / 7
2026-08-01	$-1.63	$10,000,000	6 / 5
2026-08-02	$-1.63	$10,000,000	6 / 5
2026-08-03	$-1.63	$11,428,570	8 / 7
2026-08-04	$-1.63	$11,428,570	8 / 7
2026-08-05	$-1.63	$11,428,570	8 / 7
2026-08-06	$-1.63	$10,000,000	6 / 5
2026-08-07	$-1.63	$10,000,000	6 / 5
2026-08-08	$-1.63	$10,000,000	6 / 5
2026-08-09	$-1.63	$10,000,000	6 / 5
2026-08-10	$-1.63	$11,428,570	8 / 7
2026-08-12	$-1.63	$10,000,000	6 / 5
2026-08-13	$-1.63	$11,428,570	8 / 7
2026-08-14	$-1.63	$10,000,000	6 / 5
2026-08-15	$-1.63	$10,000,000	6 / 5
2026-08-16	$-1.63	$10,000,000	6 / 5
2026-08-17	$-1.63	$10,000,000	6 / 5
2026-08-18	$-1.63	$10,000,000	6 / 5
2026-08-19	$-1.63	$10,000,000	6 / 5
2026-08-20	$-1.66	$10,000,000	6 / 5
2026-08-21	$-1.66	$10,000,000	6 / 5
2026-08-22	$-1.66	$10,000,000	6 / 5
2026-08-23	$-1.66	$10,000,000	6 / 5
2026-08-24	$-1.66	$10,000,000	6 / 5
2026-08-25	$-1.66	$10,000,000	6 / 5
2026-08-26	$-1.66	$10,000,000	6 / 5
2026-08-27	$-1.66	$10,000,000	6 / 5
2026-08-28	$-1.66	$10,000,000	6 / 5
2026-08-29	$-1.66	$10,000,000	6 / 5
2026-08-30	$-1.66	$10,000,000	6 / 5
2026-08-31	$-1.66	$10,000,000	6 / 5
2026-09-01	$-1.66	$10,000,000	6 / 5
2026-09-02	$-1.66	$10,000,000	6 / 5
2026-09-03	$-1.66	$10,000,000	6 / 5
2026-09-04	$-1.66	$10,000,000	6 / 5
2026-09-05	$-1.66	$10,000,000	6 / 5
2026-09-06	$-1.66	$10,000,000	6 / 5
2026-09-07	$-1.66	$10,000,000	6 / 5
2026-09-08	$-1.66	$10,000,000	6 / 5
2026-09-09	$-1.66	$10,000,000	6 / 5
2026-09-10	$-1.66	$10,000,000	6 / 5
2026-09-11	$-1.66	$10,000,000	6 / 5
2026-09-12	$-1.66	$10,000,000	6 / 5
2026-09-13	$-1.66	$10,000,000	6 / 5
2026-09-14	$-1.66	$10,000,000	6 / 5
2026-09-15	$-1.66	$10,000,000	6 / 5
2026-09-16	$-1.66	$10,000,000	6 / 5
2026-09-17	$-1.66	$10,000,000	6 / 5
2026-09-18	$-1.66	$10,000,000	6 / 5
2026-09-19	$-1.66	$10,000,000	6 / 5
2026-09-20	$-1.66	$10,000,000	6 / 5
2026-09-21	$-1.66	$10,000,000	6 / 5
2026-09-22	$-1.66	$10,000,000	6 / 5
2026-09-23	$-1.66	$10,000,000	6 / 5
2026-09-24	$-1.66	$10,000,000	6 / 5
2026-09-25	$-1.66	$10,000,000	6 / 5
2026-09-26	$-1.66	$10,000,000	6 / 5
2026-09-27	$-1.66	$10,000,000	6 / 5
2026-09-28	$-1.66	$10,000,000	6 / 5
2026-09-29	$-1.66	$10,000,000	6 / 5
2026-09-30	$-1.66	$10,000,000	6 / 5
2026-10-01	$-1.66	$10,000,000	6 / 5
2026-10-02	$-1.66	$10,000,000	6 / 5
2026-10-03	$-1.66	$10,000,000	6 / 5
2026-10-04	$-1.66	$10,000,000	6 / 5
2026-10-05	$-1.66	$10,000,000	6 / 5
2026-10-06	$-1.66	$10,000,000	6 / 5
2026-10-07	$-1.66	$10,000,000	6 / 5
2026-10-08	$-1.66	$10,000,000	6 / 5
2026-10-09	$-1.66	$10,000,000	6 / 5
2026-10-10	$-1.65	$10,000,000	6 / 5
2026-10-11	$-1.65	$10,000,000	6 / 5
2026-10-12	$-1.65	$10,000,000	6 / 5
2026-10-13	$-1.65	$10,000,000	6 / 5
2026-10-14	$-1.65	$10,000,000	6 / 5
2026-10-15	$-1.65	$10,000,000	6 / 5
2026-10-16	$-1.65	$10,000,000	6 / 5
2026-10-17	$-1.65	$10,000,000	6 / 5
2026-10-18	$-1.65	$10,000,000	6 / 5
2026-10-19	$-1.65	$10,000,000	6 / 5
2026-10-20	$-1.65	$10,000,000	6 / 5
2026-10-21	$-1.65	$10,000,000	6 / 5
2026-10-22	$-1.65	$10,000,000	6 / 5
2026-10-23	$-1.65	$10,000,000	6 / 5
2026-10-24	$-1.65	$10,000,000	6 / 5

Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.

Compare required revenue and earnings

Analyst view

Monthly observations

Buy / Strong BuyHoldSell / Strong Sell

Exact monthly counts

Monthly rating snapshots · fmp. Missing snapshots are not zero.
Date	Buy*	Hold
2026-05-01	7	1
2026-06-01	8	1
2026-07-01	7	1
2026-08-01	7	1
2026-09-01	7	1
2026-10-01	7	1

*Buy includes Strong Buy; Sell includes Strong Sell. Monthly counts describe the analyst mix, not the firms behind each recent action.

Latest: 7 Buy / Strong Buy · 1 Hold · 0 Sell / Strong Sell

0 upgrades0 downgrades0 maintains

Recent actions · Sep 25–Oct 24 · 0 recorded

Price-target changes

30 days

Individual price-target observations are unavailable.

0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior

How this is measured

Sep 25, 2026–Oct 24, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.

Outlook in Brief

The evidence, the remaining questions, and what comes next

What's improving

No recovery evidence is reported in the available driver assessments.

Still unresolved / key risks

Advance TH103 to Phase 3 clinical trialsDirect metric needs a verified mapping
Maintain financial stability through private placementsDirect metric needs a verified mapping
Manage CFO transition to maintain financial leadershipDirect metric needs a verified mapping

Next proof point

Nov 11, 2026

Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.

Review earnings

Bottom line

3 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.

The dated weekly assessment and its assumptions are available in Read detailed Outlook.

Historical risk context

Observed price history; separate from operating scenarios

Price sensitivity

2.5%Typical daily move · historical

Downside history

-83.0%Maximum drawdown · trailing year

Read detailed Outlook Company context, assumptions & risks

KALARIS THERAPEUTICS INC outlook in detail

The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.

Updated Oct 24, 2026

What kind of bet this is

This is a speculative clinical-development business, not an established earnings compounder. The long-term thesis is in a watch state: TH103 is progressing, but confidence is low and recent performance remains below its industry cohort.

What's priced into KALARIS THERAPEUTICS INC

The snapshot provides no valuation multiple or clear expectations estimate, so it does not support a firm view on whether KLRS is cheap, fair, or expensive versus peers. It reports low valuation fragility, meaning no listed warning signs are concentrating market fragility, but that does not resolve the expectations gap.

What the fundamentals likely do

Near term, a 47% estimated miss probability and high-risk profile make the next report important, despite an earnings beat in August. Management says TH103 remains on track for preliminary data in the first half of 2027 and Phase 3 initiation by year-end 2027; cash declined from the first to second quarter but is reported to fund operations into Q4 2027. The CFO transition and filed litigation add uncertainty, while the stronger Healthcare sector backdrop is a tailwind rather than proof of company-level progress.

What KALARIS THERAPEUTICS INC hinges on

The multi-year thesis depends on TH103 trial progress and whether preliminary data arrive on the stated timeline, alongside continued cash discipline. Near term, a guidance cut or further weakening in jobs data could pressure the business backdrop, while continued strong results and guidance from sector bellwethers could support Healthcare sentiment.